Cogentix Medical Inc /de/ (CGNT): Lewis C Pell , director of Cogentix Medical Inc /de/ purchased 500,000 shares on May 31, 2016. The Insider buying transaction was reported by the company on Jun 1, 2016 to the Securities and Exchange Commission. The shares were purchased at $0.79 per share for a total value of $394,500.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 22, 2015, Kevin H Roche (director) purchased 10,000 shares at $1.65 per share price.
Cogentix Medical Inc: On Wednesday, Jun 1, 2016 heightened volatility was witnessed in Cogentix Medical Inc which led to swings in the share price. The shares opened for trading at $0.78 and hit $0.79 on the upside , eventually ending the session at $0.7502, with a gain of 5.35% or 0.0381 points. The heightened volatility saw the trading volume jump to 66,820 shares. The 52-week high of the share price is $1.74 and the company has a market cap of $19 M . The 52-week low of the share price is at $0.7121.
Cogentix Medical Inc. formerly Vision-Sciences Inc. is a medical device company. The Company designs develops manufactures and markets products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier EndoSheath technology. The Company produces and markets Endoscopes such as cystoscopes ureteroscopes laryngoscopes otoscopes sinuscopes trans-nasal esophagoscopy (TNE) and bronchoscopes for medical use and borescopes for industrial use and digital processing units (DPU). The Company offers Urgent PC Neuromodulation System a nerve stimulation device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). It also offers Macroplastique an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence. It markets additional bulking agents: PTQ for the treatment of fecal incontinence and the VOX for vocal cord augmentation.